- Home
- AKRO vs VYX Comparison
AKRO vs VYX Comparison
Compare AKRO & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- VYX
- Stock Information
- Founded
- AKRO 2017
- VYX 1881
- Country
- AKRO United States
- VYX United States
- Employees
- AKRO N/A
- VYX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- VYX
- Sector
- AKRO Health Care
- VYX
- Exchange
- AKRO Nasdaq
- VYX Nasdaq
- Market Cap
- AKRO 2.0B
- VYX 2.1B
- IPO Year
- AKRO 2019
- VYX N/A
- Fundamental
- Price
- AKRO $28.08
- VYX $13.42
- Analyst Decision
- AKRO Strong Buy
- VYX Strong Buy
- Analyst Count
- AKRO 8
- VYX 7
- Target Price
- AKRO $46.83
- VYX $16.33
- AVG Volume (30 Days)
- AKRO 594.3K
- VYX 1.4M
- Earning Date
- AKRO 02-27-2025
- VYX 02-27-2025
- Dividend Yield
- AKRO N/A
- VYX N/A
- EPS Growth
- AKRO N/A
- VYX N/A
- EPS
- AKRO N/A
- VYX 4.40
- Revenue
- AKRO N/A
- VYX $3,592,000,000.00
- Revenue This Year
- AKRO N/A
- VYX N/A
- Revenue Next Year
- AKRO N/A
- VYX N/A
- P/E Ratio
- AKRO N/A
- VYX $3.06
- Revenue Growth
- AKRO N/A
- VYX 956.47
- 52 Week Low
- AKRO $15.32
- VYX $10.87
- 52 Week High
- AKRO $37.00
- VYX $17.39
- Technical
- Relative Strength Index (RSI)
- AKRO 41.87
- VYX 38.06
- Support Level
- AKRO $27.45
- VYX $13.51
- Resistance Level
- AKRO $28.76
- VYX $14.09
- Average True Range (ATR)
- AKRO 1.49
- VYX 0.56
- MACD
- AKRO -0.12
- VYX -0.13
- Stochastic Oscillator
- AKRO 17.98
- VYX 1.03
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.